Barman Balfour, J.A.; Wiseman, L.R.
March 1999
Drugs;Mar1999, Vol. 57 Issue 3, p363
Academic Journal
â–´ Moxifloxacin is a new fluoroquinolone antibacterial agent with a broad spectrum of activity, encompassing Gram-negative and Gram-positive bacteria. It has improved activity against Gram-positive species (including staphylococci, streptococci, enterococci) and anaerobes compared with ciprofloxacin. This is offset by slightly lower activity against pseudomonal species and Enterobacteriaceae. â–´ In common with other fluoroquinolones, moxifloxacin attains good penetration into respiratory tissues and fluids and its bioavailability is substantially reduced by coadministration with an antacid or iron preparation. However, moxifloxacin does not interact with theophylline or warfarin. â–´ In clinical trials in patients with community-acquired pneumococcal pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB) or acute sinusitis, moxifloxacin 400mg once daily achieved bacteriological and/or clinical success rates of approximately 90% or higher. â–´ Moxifloxacin was as effective as amoxicillin 1g 3 times daily and clarithromycin 500mg twice daily in CAP and as effective as clarithromycin in AECB. In patients with sinusitis, a 7-day course of moxifloxacin 400mg once daily was as effective as a 10-day course of cefuroxime axetil 250mg twice daily. â–´ In contrast to some other fluoroquinolones, moxifloxacin appears to have a low propensity for causing phototoxic and CNS excitatory effects. The most common adverse events are gastrointestinal disturbances.


Related Articles

  • Routine Cycling of Antimicrobial Agents as an Infection-Control Measure. Fridkin, Scott K. // Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1438 

    Antimicrobial cycling is the deliberate, scheduled removal and substitution of specific antimicrobials or classes of antimicrobials within an institutional environment (either hospital-wide or confined to specific units) to avoid or reverse the development of antimicrobial resistance. True...

  • MOXIFLOXACIN: a once-daily, fourth-generation fluoroquinolone antibiotic Product Profile.  // Formulary;Jun2002 Supplement 3, Vol. 37 Issue 6, p9 

    Focuses on moxifloxacin, a fourth-generation fluorinated quinolone. Chemistry and mechanism of action; Antimicrobial activity; Clinical and microbial efficacy.

  • Antimicrobial Activity of Moxifloxacin and Levofloxacin Photodegradation Products. Tobin, C.M.; Sunderland, J.; MacGowan, A.P.; Hedges, A.J.; White, L.O. // Drugs;Dec1999 Supplement 2, Vol. 58 Issue 6, p144 

    Investigates the antimicrobial activity of the photodegradation products of moxifloxacin and levofloxacin. Materials and methods; Results; Discussion.

  • Update on the Appropriate Use of Meropenem for the Treatment of Serious Bacterial Infections. Kollef, Mann H. // Clinical Infectious Diseases;9/15/2008 Supplement 1, Vol. 47, pS1 

    The article discusses various reports published within the issue, including the article about the use of broad spectrum antimicrobials in treating bacterial infections and another on the pharmacokinetic and pharmacodynamic properties of meropenem.

  • Levofloxacin: A Review of its Use in the Treatment of Bacterial Infections in the United States. Croom, Katherine F.; Goa, Karen L. // Drugs;2003, Vol. 63 Issue 24, p2769 

    Levofloxacin (Levaquin[sup ®]) is a fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive and Gram-negative bacteria and atypical respiratory pathogens. It is active against both penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae....

  • Tuning natural antimicrobials to improve their effectiveness at battling superbugs.  // Biomedical Market Newsletter;9/12/2011, Vol. 21, p479 

    The article reports on a study at the Institute of Food Research which explores the use of virus-produced proteins that destroy bacterial cells to fight against dangerous microbial infections.

  • Antibiotic Therapy for Bacterial Enterocolitis: A Comprehensive Review. Wolf, David C.; Giannella, Ralph A. // American Journal of Gastroenterology;Oct1993, Vol. 88 Issue 10, p1667 

    The treatment of bacterial enterocolitis is a major health care issue throughout the world. Many cases of diarrhea due to invasive bacterial pathogens can be managed by oral rehydration, only. Nonetheless, antibiotics play an invaluable role in the management of patients suffering from severe...

  • Gatifloxacin: A Review of its Use in the Treatment of Bacterial Infections in the US. Keam, Susan J.; Croom, Katherine F.; Keating, Gillian M. // Drugs;2005, Vol. 65 Issue 5, p695 

    Gatifloxacin (Tequin®) is an 8-methoxy fluoroquinolone approved in the US for use in the treatment of community-acquired pneumonia (CAP), acute exacerbations of chronic bronchitis (AECB), acute sinusitis, uncomplicated and complicated urinary tract infections (UTIs), pyelonephritis,...

  • Antibiotics: Knowing when they're not needed. Johnson, Teddi Dineley // Nation's Health;Oct2010, Vol. 40 Issue 8, p15 

    The article emphasizes the need for patients and parents to be aware of the limitations of antibiotic treatments, because taking antibiotics when they are not needed or misusing them increases the risk that an infection a patient will get later will be resistant to these treatments. It cites...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics